首页>
外国专利>
Use of cannabidiol in the treatment of seizures associated with encephalitis
Use of cannabidiol in the treatment of seizures associated with encephalitis
展开▼
机译:在癫痫症相关的癫痫发作中使用大麻
展开▼
页面导航
摘要
著录项
相似文献
摘要
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with encephalitis is provided. The seizures associated with encephalitis may be atonic, focal seizures with impairment, focal seizures without impairment, and focal seizures with secondary generalisation. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be selected from the group consisting of: levetiracetam, clobazam, lacosamide, and lamotrigine. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein patients diagnosed with encephalitis had a decrease in the amount of seizures after dosing with the CBD preparation and concomitant AEDs.
展开▼
机译:提供了用于治疗与脑炎相关的癫痫发作的大麻(CBD)制剂。 与脑炎有关的癫痫发作可能是休息,焦点癫痫发作,障碍,没有损害的焦点癫痫发作,以及具有二次泛化的局灶性癫痫发作。 CBD制剂可包含大于或等于98%(w / w)CBD,小于或等于2%(w / w)其他大麻素。 CBD制剂可包含从大麻植物材料中分离的CBD,或者可以是合成的CBD。 CBD制剂可与一种或多种伴随的抗癫痫药物(AED)组合使用。 一种或多种伴随的AED可以选自:Levetiracetam,Clobazam,Lacosamide和乳草酰胺。 CBD的剂量可以在5mg / kg /天至50mg / kg /天之间。 公开了一种临床试验,其中患有CBD制剂和伴随AEDs的癫痫发作后,诊断患有脑炎的患者的癫痫发作量减少。
展开▼